News / Health

Test of New Dengue Vaccine Shows Promise

A boy with dengue fever receives medical oxygen while laying on a bed at the Quirino hospital in Quezon city in the suburbs of Manila, August 14, 2012.A boy with dengue fever receives medical oxygen while laying on a bed at the Quirino hospital in Quezon city in the suburbs of Manila, August 14, 2012.
x
A boy with dengue fever receives medical oxygen while laying on a bed at the Quirino hospital in Quezon city in the suburbs of Manila, August 14, 2012.
A boy with dengue fever receives medical oxygen while laying on a bed at the Quirino hospital in Quezon city in the suburbs of Manila, August 14, 2012.
Faith Lapidus
A clinical trial of a new vaccine against dengue fever shows progress toward fighting the most common mosquito-borne disease.  The drug is less successful than hoped, but seems to be effective at preventing three of the four related viruses that cause dengue.

Dengue fever increasing

Dengue fever is endemic across the tropics, with more than 2.5 billion people in 128 countries at risk. Symptoms can range from aches and fever to circulatory failure, coma and death.  Some 21,000 people die of dengue each year, and the number of cases is increasing, including outbreaks in the southeastern United States.

There is no vaccine available to prevent dengue fever.  Part of the difficulty in developing one is that there are four different but related types of the disease.  Those who recover from infection by one type gain lifetime immunity, but only against that type.  Scott Halstead, of the Dengue Vaccine Initiative, explains that they are still at risk of infection with one of the other types.

"Dengue normally produces a short acute febrile disease, sort of a flu-like disease which ends in a rash, and when you're convalescent, you have life-long immunity to the type you've been infected with, say Type 1.  But you are susceptible then to either type 2 or 3 or 4, and what we've learned is that two different infections - with say, Type 1 and Type 2 - can result in a very severe catastrophic disease called dengue hemorrhagic fever, and this occurs all over the tropical world, mostly in Asia and the American tropics," Halstead explained.

New vaccine

That is why researchers are focused on developing a so-called tetravalent vaccine, modeled on the successful yellow fever vaccine, combining weakened versions of all four types of dengue virus into a single drug. 

Halstead, who was not involved in the new clinical trial, says the pharmaceutical company, Sanofi Pasteur, took a molecular approach to creating its vaccine.

"They actually spliced the gene for each of the four dengue viruses into a yellow fever backbone.  So this is a combined vaccine called a chimera, combining the yellow fever replicative machinery and the dengue surface proteins," he said. "But it is a vaccine mixture of dengue 1, 2, 3 and 4."

In the first trial to determine whether a vaccine could actually prevent the disease, Sanofi's drug was tested in 4,000 school children in Thailand.  The children got three doses of either the vaccine or a placebo.  Spacing the shots six months apart was meant to mimic the natural immune response people develop over time.  Two years later, the vaccine seemed to have protected the children against three of the four strains, but not the most common type of the virus, which accounts for about 40 percent of severe dengue cases worldwide.

But the results show that the vaccine is safe, and technologically possible.

Although Halstead and many other dengue experts expressed disappointment that Sanofi's vaccine was not more effective, they regard it as an important step forward.

"The problem is, can we use a vaccine that only protects against three?  In my commentary that I wrote for The Lancet, I speculated that maybe, if you could really give enough of a three-component vaccine to stop transmission, you'd actually leave just one virus, and one virus all by itself won't cause dengue hemorrhagic fever.  So a lot of the really serious problems caused by dengue viruses might be controlled with a three-component vaccine," said Halstead.

Sanofi is already testing its new vaccine in large Phase 3 trials involving more than 30,000 people in 10 countries, with results expected in 2014.  A report about the Phase 2 trial, and Dr. Halstead's commentary, appear in the medical journal, The Lancet.

You May Like

UN: 1 Million Somalis at Risk of Hunger

Group warns region is in dire need of humanitarian aid, with at least 200,000 children under age of five acutely malnourished as drought hits southern, central part of nation More

Human Rights Groups Allege Supression of Freedoms in Thailand

Thailand’s military, police have suppressed release of independent report assessing human rights in kingdom during first 100 days of latest coup More

Jennifer Lawrence Contacts FBI After Nude Photos Hacked

'Silver Linings Playbook' actress' photos were posted on image-sharing forum 4chan; Federal Bureau of Investigations is looking into matter More

Featured Videos

Your JavaScript is turned off or you have an old version of Adobe's Flash Player. Get the latest Flash player.
Ukraine Schools Resume Classes, Donate to Government Forcesi
X
September 02, 2014 12:58 PM
A new school year has started in Ukraine but thousands of children in the war-torn east are unable to attend because of ongoing clashes with pro-Russia rebels. In Ukraine's capital, patriotic education has become the norm along with donations to support injured security forces fighting to take back rebel-held areas. VOA's Daniel Schearf reports from Kyiv.
Video

Video Ukraine Schools Resume Classes, Donate to Government Forces

A new school year has started in Ukraine but thousands of children in the war-torn east are unable to attend because of ongoing clashes with pro-Russia rebels. In Ukraine's capital, patriotic education has become the norm along with donations to support injured security forces fighting to take back rebel-held areas. VOA's Daniel Schearf reports from Kyiv.
Video

Video US Detainees Want Negotiators for Freedom in North Korea

The three U.S. detainees held in North Korea were permitted to speak with foreign media Monday. The government of Kim Jong Un restricted the topics of the questions, and the interviews in Pyongyang were limited to five minutes. Each of the men asked Washington to send a representative to Pyongyang to secure his release. VOA’s Carolyn Presutti has our story.
Video

Video Internet, Technology Offer New Tools for Journalists

The Internet and rapidly evolving technology is quickly changing how people receive news and how journalists deliver it. There are now more ways to tell a story than ever before. One school in Los Angeles is teaching the next generation of journalists with the help of a state-of-the-art newsroom. Elizabeth Lee has this report.
Video

Video Turkmen From Amerli Describe Survival of IS Siege

Over the past few weeks, hundreds of Shi'ite Turkmen have fled the town of Amerli seeking refuge in the northern city of Kirkuk. Despite recent military gains after U.S. airstrikes that were coordinated with Iraqi and Kurdish forces, the situation remains dire for Amerli’s residents. Sebastian Meyer went to Kirkuk for VOA to speak to those who managed to escape.
Video

Video West Africa Ebola Vaccine Trials Possible by Early 2015

A U.S. health agency is speeding up clinical trials of a possible vaccine against the deadly Ebola virus that so far has killed more than 1,500 people in West Africa. If successful, the next step would be a larger trial in countries where the outbreak is occurring. VOA's Carol Pearson has more.
Video

Video Survivors Commemorate 70th Anniversary of Nazi Liquidation of Jewish Ghetto

When the German Nazi army occupied the Polish city of Lodz in 1939, it marked the beginning of a long nightmare for the Jewish community that once made up one third of the population. Roughly 200,000 people were forced into the Lodz Ghetto. Less than 7,000 survived. As VOA’s Kane Farabaugh reports, some survivors gathered at the Union League Club in Chicago on the 70th anniversary of the liquidation of the Lodz Ghetto to remember those who suffered at the hands of the Nazi regime.
Video

Video Cost to Raise Child in US Continues to Rise

The cost of raising a child in the United States continues to rise. In its latest annual report, the U.S. Department of Agriculture says middle income families with a child born in 2013 can expect to spend more than $240,000 before that child turns 18. And sending that child to college more than doubles that amount. VOA’s Deborah Block visited with a couple with one child in Alexandria, Virginia, to learn if the report reflects their lifestyle.
Video

Video Chaotic Afghan Vote Recount Threatens Nation’s Future

Afghanistan’s troubled presidential election continues to be rocked by turmoil as an audit of the ballots drags on. The U.N. says the recount will not be completed before September 10. Observers say repeated disputes and delays are threatening the orderly transfer of power and could have dangerous consequences. VOA correspondent Meredith Buel reports.

AppleAndroid